Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock

2026-01-27 03:59:15 ET

It's been over a year since I covered Fulgent Genetics ( FLGT ), a biotech company focusing on cancer cures. On my first look, I saw a company trading significantly below the net value of its cash and marketable securities, which had a few drug candidates in the pipeline, giving downside protection with the possibility of upside. I also liked that the company was heavily owned by insiders and that by investing in Fulgent, investors could align their money with a competent management team led by Ming Hsieh, the longtime CEO who owns more than 28% of the company....

Read the full article on Seeking Alpha

For further details see: